These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2260923)

  • 61. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
    Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection.
    Portetelle D; Limbach K; Burny A; Mammerickx M; Desmettre P; Riviere M; Zavada J; Paoletti E
    Vaccine; 1991 Mar; 9(3):194-200. PubMed ID: 1645899
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Induction of neutralizing antibodies by varicella-zoster virus gpII glycoprotein expressed from recombinant vaccinia virus.
    Massaer M; Haumont M; Place M; Bollen A; Jacobs P
    J Gen Virol; 1993 Mar; 74 ( Pt 3)():491-4. PubMed ID: 8383181
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice.
    Gould EA; Buckley A; Barrett AD; Cammack N
    J Gen Virol; 1986 Mar; 67 ( Pt 3)():591-5. PubMed ID: 3950582
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice.
    Desprès P; Dietrich J; Girard M; Bouloy M
    J Gen Virol; 1991 Nov; 72 ( Pt 11)():2811-6. PubMed ID: 1834798
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development and Characterization of Monoclonal Antibodies to Yellow Fever Virus and Application in Antigen Detection and IgM Capture Enzyme-Linked Immunosorbent Assay.
    Adungo F; Yu F; Kamau D; Inoue S; Hayasaka D; Posadas-Herrera G; Sang R; Mwau M; Morita K
    Clin Vaccine Immunol; 2016 Aug; 23(8):689-97. PubMed ID: 27307452
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice.
    Zulueta A; Martín J; Hermida L; Alvarez M; Valdés I; Prado I; Chinea G; Rosario D; Guillén G; Guzmán MG
    Virus Res; 2006 Oct; 121(1):65-73. PubMed ID: 16781791
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain.
    Putri DH; Sudiro TM; Yunita R; Jaya UA; Dewi BE; Sjatha F; Konishi E; Hotta H; Sudarmono P
    Jpn J Infect Dis; 2015; 68(5):357-63. PubMed ID: 25766602
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.
    Monath TP; Arroyo J; Levenbook I; Zhang ZX; Catalan J; Draper K; Guirakhoo F
    J Virol; 2002 Feb; 76(4):1932-43. PubMed ID: 11799188
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
    De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
    Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine Candidates.
    Govindarajan D; Guan L; Meschino S; Fridman A; Bagchi A; Pak I; ter Meulen J; Casimiro DR; Bett AJ
    PLoS One; 2016; 11(3):e0152209. PubMed ID: 27008550
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies.
    Schlesinger JJ; Walsh EE; Brandriss MW
    J Gen Virol; 1984 Oct; 65 ( Pt 10)():1637-44. PubMed ID: 6208313
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
    Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
    J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of protein conformation in the processing of dengue virus type 2 nonstructural polyprotein precursor.
    Zhang L; Padmanabhan R
    Gene; 1993 Jul; 129(2):197-205. PubMed ID: 8325506
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Processing of dengue virus type 2 structural proteins containing deletions in hydrophobic domains.
    Gruenberg A; Wright PJ
    Arch Virol; 1992; 122(1-2):77-94. PubMed ID: 1729986
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structural analysis and immunogenicity of recombinant major envelope protein (rA27L) of buffalopox virus, a zoonotic Indian vaccinia-like virus.
    Kumar A; Yogisharadhya R; Bhanuprakash V; Venkatesan G; Shivachandra SB
    Vaccine; 2015 Oct; 33(41):5396-5405. PubMed ID: 26319070
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge.
    Feighny R; Burrous J; Putnak R
    Am J Trop Med Hyg; 1994 Mar; 50(3):322-8. PubMed ID: 8147490
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I.
    Kutinová L; Ludvíková V; Krystofová J; Otavová M; Simonová V; Nĕmecková S; Hainz P; Vonka V
    Vaccine; 1996 Aug; 14(11):1045-52. PubMed ID: 8879101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.